Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thyroid Neoplasms 2Esophageal Neoplasms 2Stereotactic Body Radiation Therapy 1Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 11Blood Specimen Collection 10Colonoscopy 8Psychiatric Rehabilitation 7Immunohistochemistry 6Drug Therapy 6Biopsy 6Polymerase Chain Reaction 5Mental Status and Dementia Tests 5Surgical Procedures, Operative 4Observation 4Immunoenzyme Techniques 4Gene Expression Profiling 4Endoscopic Mucosal Resection 4Colectomy 4Amplified Fragment Length Polymorphism Analysis 4Watchful Waiting 3Polyethylene Glycols 3Microarray Analysis 3Magnetic Resonance Spectroscopy 3Laparoscopy 3Genetic Testing 3Exercise 3Endoscopy 3Chromosome Mapping 3Bevacizumab 3Specimen Handling 2Reverse Transcriptase Polymerase Chain Reaction 2Radiotherapy 2Mass Spectrometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Colonic Neoplasms × anlotinib × Clear all
NCT06573424 2025-05-01

Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Completed
124 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡